Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 182

Sacituzumab Govitecan before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Partial Cystectomy and Extended Pelvic Lymph Node Dissection with Standard of Care Systemic Therapy for the Treatment of Muscle-Invasive Bladder Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients with Metastatic Urothelial Bladder Cancer and other Solid Tumors
Status: Active
Location: Northwestern University, Chicago, Illinois
Pemigatinib before Surgery for the Treatment of Recurrent Low- or Intermediate Risk Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 6 locations
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Adjuvant Sacituzumab Govitecan and Nivolumab for the Treatment of Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Intravesical Gemcitabine and Docetaxel for the Treatment of Non-muscle Invasive Bladder Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Intravesical Gemcitabine and Docetaxel for the Treatment of Low Grade Intermediate Risk Bladder Cancer
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Patritumab Deruxtecan for the Treatment of Patients with Newly Diagnosed or Recurrent Brain Metastases
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Enfortumab Vedotin and Pembrolizumab Plus Radiation Therapy for the Treatment of Muscle Invasive Bladder Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Stereotactic Radiotherapy and Enfortumab Vedotin for the Treatment of Patients with Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Enfortumab Vedotin with Concurrent Radiation Therapy for the Treatment of Locally Advanced Bladder Cancer, CONSOLIDATE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Sacituzumab Govitecan in Combination with Adaptive Radiation Therapy for Treatment of Patients with Muscle Invasive Bladder Cancer, RAD-SG Study
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Personalized Cancer Vaccine for the Treatment of Muscle-invasive Bladder Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients with Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination with Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California